Momentum Biotechnologies Acquires OmicScouts

• Momentum Biotechnologies has acquired OmicScouts GmbH, a Munich-based contract research organisation (CRO) specialising in mass spectrometry-based proteomics.

• The acquisition enhances Momentum’s drug discovery capabilities and marks its expansion into the European market.

Momentum Biotechnologies has successfully acquired OmicScouts GmbH, a contract research organisation (CRO) based in Munich, Germany. The move strengthens Momentum’s position in mass spectrometry-based drug discovery and enables geographic expansion into the European market. OmicScouts will continue operations under its new name, OmicScouts, a Momentum Biotechnologies Company.

With this acquisition, Momentum integrates OmicScouts’ portfolio of validated proteomic assays, enhancing its service offerings. The combined capabilities will allow biopharmaceutical clients to progress seamlessly from high-throughput screening to cell-based assays while identifying novel drug targets and biomarkers.

Can Ozbal, Ph.D., founder and CEO of Momentum Biotechnologies, highlighted the strategic importance of the acquisition: “With the addition of OmicScouts’ leading chemoproteomic capabilities, we are now able to take projects beyond hit identification to interrogate target engagement, selectivity/specificity, and global drug response.”

OmicScouts’ co-founder and CEO, Hannes Hahne, Ph.D., will take on the role of President at Momentum and join its global executive leadership team. Two OmicScouts co-founders, Mathias Wilhelm, Ph.D., and Bernhard Kuster, Ph.D.,will join Momentum’s Scientific Advisory Board. The acquisition is expected to enhance Momentum’s ability to provide innovative solutions to drug developers worldwide.